Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome-Reference-Cited by-同舟云学术

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

Published:2017-06-14 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Allegretti Andrew S¹,Israelsen Mads²,Krag Aleksander²,Jovani Manol³,Goldin Alison H⁴,Schulman Allison R⁴,Winter Rachel W⁴,Gluud Lise Lotte⁵

Affiliation:

1. Massachusetts General Hospital; Division of Nephrology, Department of Medicine; Boston USA MA 02114

2. Odense University Hospital; Department of Gastroenterology and Hepatology; Sdr. Boulevard 29 Odense C Denmark 5000

3. Massachusetts General Hospital and Harvard Medical School; Division of Gastroenterology; 55 Fruit St Boston USA MA 02114

4. Brigham and Women's Hospital; Division of Gastroenterology, Hepatology and Endoscopy; Boston USA MA 02115

5. Copenhagen University Hospital Hvidovre; Gastrounit, Medical Division; Kettegaards Alle Hvidovre Denmark 2650

Publisher

Wiley

Subject

Pharmacology (medical)

Reference62 articles.

1. A randomized, placebo-controlled, double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin: the REVERSE trial design;Boyer;Open Access Journal of Clinical Trials,2012

2. Boyer TD Sanyal AJ Wong F Frederick RT Lake JR O'Leary JG Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1 Gastroenterology 2016 1579 89.e2

3. Terlipressin in the treatment of hepatorenal syndrome (HRS): a double blind cross-over study;Hadengue;Hepatology (Baltimore, Md.),1995

4. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome;Hadengue;Journal of Hepatology,1998

5. Randomized, comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepatorenal syndrome;Martin-Llahi;Journal of Hepatology,2007

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of hepatic hydropericardium with open drainage, maximal medical therapy and terlipressin;BMJ Case Reports;2024-01

2. Outcomes of patients with hepatorenal syndrome undergoing liver transplantation in the era of terlipressin;European Journal of Gastroenterology & Hepatology;2023-06-06

3. Terlipressin reduces the incidence of delayed graft function in kidney transplant recipients;2023-05-30

4. Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?;Hepatology Research;2022-11-08

5. Terlipressin: Leading the Water to the Thirsty*;Critical Care Medicine;2022-09-12